Coradil AB

Drug candidate for Corona

A Swedish group including Anders Milton, physician and former chairman and CEO of the Swedish Medical Association and Johan de Faire, chemist, Jan Ståhlberg (founder of Trill Impact and former vice CEO of EQT) and Per Berglund (founder of Nordiska Kreditmarknadsbolaget) are included.

The group is working on a preparation that is hoped to quickly reduce the viral load of coronavirus infected (covid-19). A probiotic has been reinforced with zinc, a necessary trace metal and known inhibitor of this virus type. In this form, zinc can enter the host cell of the virus and prevent the cell from dividing. Infection cannot then spread, the symptoms subside and the recovery progresses quickly.

The group now intends to conduct a clinical study on a limited number of coronary-infected patients to confirm the effects and results of virus infections on animals.

Read more

We are Coradil

Anders Milton

Anders Milton

Doctor and former chairman and CEO of the Swedish Medical Association
Johan De Faire

Johan De Faire

chemist
Jan Ståhlberg

Jan Ståhlberg

founder of Trill Impact and former vice CEO of EQT
Per Berglund

Per Berglund

founder of Nordiska Kreditmarknadsbolaget
Coradil AB
Org.nr: 559244-7170

Contact Us